Rice University researchers have developed a groundbreaking innovation in the field of neuroscience: resettable serum markers that provide clearer brain activity signals. This development is a significant step forward in understanding neurological diseases and the intricate workings of the brain. The team's approach involves using engineered serum markers, small proteins produced by targeted brain cells, which can be measured through a simple blood test. These markers, known as released markers of activity (RMAs), offer a sensitive tool for monitoring brain activity, but their long half-life can sometimes obscure subtle changes in biological signals. To address this challenge, the researchers designed an erasable marker that can be cleaved by an enzyme, effectively resetting the signal and allowing for new readings. This innovative approach has the potential to revolutionize diagnostic capabilities, enabling more precise detection of problems and changes in patient responses to treatment. The study, published in the Proceedings of the National Academy of Sciences, demonstrates the successful removal of about 90% of the RMAs' background signal within half an hour, enabling the observation of subtle gene-expression changes that were previously undetectable. The researchers also showed that they could repeat this process and measure the marker's reappearance, providing a clearer picture of gene activity over time. This method could eventually lead to more accurate and minimally invasive testing, allowing clinicians to detect issues and measure treatment responses with greater precision. The project's implications extend beyond neurology, as the ability to edit markers inside the body could be tuned for various diagnostic purposes, including tumor detection and lung disease diagnosis using urine tests. This achievement is a testament to Rice University's commitment to brain research and health innovations, aligning with the mission of the Rice Brain Institute, which aims to accelerate technologies for understanding and treating brain disorders.
